Previous 10 | Next 10 |
Market Assessment Enanta ( ENTA ) is a commercial-stage small market cap ($1.8B) biopharma that has established itself as an innovator of effective therapeutics for the viral liver disease, HCV infection, through the approval of paritaprevir and glecaprevir. Its license agreement with Ab...
NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at t...
Intercept Pharmaceuticals (NASDAQ: ICPT ) has priced its public offering of 2.4M common shares at $83.50 per share. Underwriters over-allotment is an additional 360K shares. Concurrently, it will sell 119,760 shares held by investor Samsara BioCapital. Yesterday's close was $83.90. More ...
NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has priced its underwritten pub...
CymaBay Therapeutics ( CBAY ) : The company announced first quarter financial results, with management highlighting the fact that enrollment was completed one quarter ahead of schedule in the phase 2b study of seladelpar in NASH patients (52-week, dose-ranging trial). Topline data for chang...
Gilead Sciences ( GILD ) seemed to have found its stride after reporting its latest earnings for Q1 2019 . That's because it reported a really good quarter. So much so that earnings were 28% higher for the quarter. A big reason earnings came out so well is because of the HIV franchise, whic...
NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it is commencing an underwrit...
Intercept Pharmaceuticals, Inc. (ICPT) Q1 2019 Earnings Conference Call May 08, 2019 08:30 AM ET Company Participants Justine O'Malley - Vice President, Corporate Affairs Mark Pruzanski - Chief Executive Officer Jerry Durso - Chief Operating Officer Sandip Kapadia - Chief Finan...
Intercept Pharma ( ICPT ) Q1 results : Revenues: $52.3M (+45.3%). More news on: Intercept Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Intercept Pharma (NASDAQ: ICPT ): Q1 GAAP EPS of -$3.03 misses by $0.43 . More news on: Intercept Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...